Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941970 | 0.92 | GAA (0.33) | GAA | |
| SCHEMBL6896468 | 0.88 | GAA (0.40) | GAA | |
| SCHEMBL180892 | 0.88 | GAA (0.40) | GAA | |
| Methane SCHEMBL27944275 | 0.86 | GAA (0.39) | GAA | |
| Acetic Acid SCHEMBL27526894 | 0.85 | GAA (0.38) | GAA | |
| Glycerin SCHEMBL28270843 | 0.83 | GAA (0.36) | GAA | |
| SCHEMBL9690679 | 0.82 | GAA (0.33) | GAA | |
| SCHEMBL27812014 | 0.82 | GAA (0.33) | GAA | |
| SCHEMBL4081023 | 0.82 | GAA (0.33) | GAA | |
| SCHEMBL4268176 | 0.80 | PDE4A (0.32) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1009377-A4 | MEDICAL USES OF PYRUVATES | UNIV CASE WESTERN RESERVE (US) | 2004-01-21 | — | — | EP | claimed |
| US-6086789-A | SKIN INJURIES | CASE WESTERN RESERVE UNIVERSITY (US) | 2000-07-11 | — | — | US | claimed |
| EP-1009377-A1 | MEDICAL USES OF PYRUVATES | Case Western Reserve University (US) | 2000-06-21 | — | — | EP | claimed |
| US-5876916-A | ADMINISTRATION OF GLYCEROL-PYRUVATE OR HYDROXYACETONE PYRUVATE ESTER WITH BIOCOMPATIBLE CARRIER TO MAMMALS; AS HIGH CALORIE FOOD, ANTICHOLESTEROL AGENTS, ANTIISHEMIC AGENTS, ORGAN PRESERVATIVE, ANTIDIABETIC AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0888267-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998051277-A1 | MEDICAL USES OF PYRUVATES | CASE WESTERN RESERVE UNIVERSITY (US) | 1998-11-19 | — | — | WO | claimed |
| WO-1997034856-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-09-25 | — | — | WO | claimed |
| US-7417071-B2 | Antioxidant triacylglycerols and lipid compositions | ALBERTA RESEARCH COUNCIL INC. (CA) | 2008-08-26 | — | — | US | disclosed |
| US-7041840-B2 | Antioxidant triacylglycerols and lipid compositions | ALBERTA RESEARCH COUNCIL INC. (CA) | 2006-05-09 | — | — | US | disclosed |
| US-20050165101-A1 | ANTIOXIDANT TRIACYLGLYCEROLS AND LIPID COMPOSITIONS | ALBERTA INNOVATES - TECHNOLOGY FUTURES (CA) | 2005-07-28 | — | — | US | disclosed |
| US-20040122093-A1 | delivers essential or beneficial fatty acids in an optimal manner with respect to stability and biosorptivity | ALBERTA RESEARCH COUNCIL INC. (CA) | 2004-06-24 | — | — | US | disclosed |
| EP-1430782-A1 | Antioxidant triacylglycerols and lipid compositions | Alberta Research Council, Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| EP-1009377-A4 | MEDICAL USES OF PYRUVATES | UNIV CASE WESTERN RESERVE (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6086789-A | SKIN INJURIES | CASE WESTERN RESERVE UNIVERSITY (US) | 2000-07-11 | — | — | US | disclosed |
| EP-1009377-A1 | MEDICAL USES OF PYRUVATES | Case Western Reserve University (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1998051277-A1 | MEDICAL USES OF PYRUVATES | CASE WESTERN RESERVE UNIVERSITY (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165101-A1 | ANTIOXIDANT TRIACYLGLYCEROLS AND LIPID COMPOSITIONS | LIPC, GPX4, GPX1 | GAA 569/4885 |
| US-20040122093-A1 | delivers essential or beneficial fatty acids in an optimal manner with respect to stability and biosorptivity | ELOVL1, LIPC, TTPA | GAA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.